Wolfgang Miesbach /LinkedIn
Sep 16, 2025, 02:44
Wolfgang Miesbach Highlights First Inhibitor Case After Hemophilia A Gene Therapy (Giroctocogene Fitelparvovec)
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“First reported inhibitor development in haemophilia A gene therapy Presented by Davide Matino at BIC meeting at Phase 3 giroctocogene fitelparvovec (AAV6, 3×10¹³ vg/kg, n=74).
Patient Profile:
- Genetic: Intron 22 inversion
- History: ITP + splenectomy
- Comorbidities: HCV & HIV co-infection
- Experience: 6,000 exposure days with FVIII
Clinical Timeline:
- Peak FVIII (day 75 after gene therapy): 441.7%
- Post-infusion: Multiple steroid courses for ↑ALT/AST
- Inhibitor development more than 1 year after treatment”
More recent insights on Hemostasis Today.
-
Nov 10, 2025, 10:16Pablo Corral on Enlicitide: The Phase 3 CORALreef HeFH Trial Brings a Major Step Forward
-
Nov 10, 2025, 10:15Laurent Bertoletti Invites You to the Joint INNOVTE and GITA Meeting on Hormones and Thrombosis
-
Nov 10, 2025, 10:15Christopher Cannon: DOAC Monotherapy Wins Again
-
Nov 10, 2025, 10:14Marieke Kruip on Sex differences in Outcomes of VKA Treatment in Patients with Mechanical Heart Valve
-
Nov 10, 2025, 10:14Ana Paula Lacombe: From Research to Bedside, Innovation in Stroke Care is Moving Fast!
-
Nov 10, 2025, 10:13Jan Sloves: Understanding Iliofemoral DVT – What You Can’t Afford to Miss
-
Nov 10, 2025, 10:12Mohamed Rawy Shares a Comprehensive Guide For Anticoagulation
-
Nov 10, 2025, 10:10Marc Carrier: Proud to Share the Results of the WAVe Study
-
Nov 10, 2025, 10:07Frederik Denorme – The New PI at the Laboratory of Cell Biology and Histology at University of Antwerp